Table 2:

Summary of the ALK-Rearranged Mesothelioma Reported in the Literature

Ref#	Age/Sex	Location/Asbestos exposure	ALK Fusion	Pathology	IHC	Tx/FU
#20	10/F	Peritoneum (19 cm) / none	ALK gene rearrangement	Biphasic	ALK pos	Surgery and adjuvant cisplatin & gemcitabine AWD 6 mo
#21	17/F 36/F 51/F	Peritoneum / none	STRN-ALK ATG16L1-ALK TPM1-ALK	2 epithelial, 1 biphasic	ALK pos BAP1 intact	Surgery (x3), adjuvant chemo (x2), HIPEC (x1) FU median survival 79 mo AWD 2, DOD 1
#22	13/F	Peritoneum / none	STRN-ALK	Epithelial	ALK pos BAP1 intact	Neoadjuvant Cisplatin and Pemetrexed surgery & HIPEC Ceritinib (good response) AWD 3 mo
#23	14/F	Peritoneum / none	STRN-ALK	Epithelial	ALK neg	Neoadjuvant Cisplatin & Pemetrexed; surgery with HIPEC; adjuvant Cisplatin and Pemetrexed LR, clinical trial NED 60 mo
#23	27/M	Peritoneum	ALK gene rearrangement (no fusion detected by NGS)	Epithelial	ALK neg	Surgery & HIPEC; LR, Cisplatin& Pemetrexed; antimesothelin tx with SS1P & Anetumab Ravtansine; Pembrolizumab; Crizotinib (4 mo, side effects) DOD 72 mo
#26	NA	Pleura	EML4-ALK	Sarcomatoid	NA	NA
#38	45/F	Pleura	EML4-ALK	Epithelial	ALK pos PD-L1 pos	Neoadjuvant Cisplatin and Pemetrexed; surgery; Carboplatin & Gemcitabine for brain mets; Pembrolizumab - good response AWD 6 mo

Pos, positive; Neg, negative; LR, local recurrence; mo, months; NA, not available